Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Yongsheng Jiang

Matched on ORCID iD 0000-0002-2861-4544; OpenAlex author ID A5021432789. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers

Papers 10

  1. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  2. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  3. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  4. Tumor-infiltrating OX40+ lymphocytes is an independent positive prognostic factor for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-022-02864-1↗
  5. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  6. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. Co-author DOI 10.18632/aging.202264↗
  7. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  8. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  9. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  10. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lingxi Jiang · 4 shared papers, 2021–2023 · strength 0.58
  2. Yongwei Sun · 5 shared papers, 2019–2022 · strength 0.46
  3. Minwei Yang · 4 shared papers, 2019–2023 · strength 0.44
  4. Cheng Xiong · 3 shared papers, 2021–2023 · strength 0.43
  5. Youwei Zhu · 3 shared papers, 2021–2023 · strength 0.43
  6. Meilin Xue · 3 shared papers, 2021–2023 · strength 0.43
  7. Hao Chen · 3 shared papers, 2021–2023 · strength 0.43
  8. Yan‐Miao Huo · 4 shared papers, 2019–2022 · strength 0.42
  9. Jian‐Yu Yang · 4 shared papers, 2019–2022 · strength 0.34
  10. Zhigang Zhang · 4 shared papers, 2019–2021 · strength 0.33
  11. Lijie Han · 2 shared papers, 2022–2023 · strength 0.29
  12. Baiyong Shen · 2 shared papers, 2022–2023 · strength 0.29
  13. Ruizhe He · 3 shared papers, 2019–2022 · strength 0.28
  14. Xueliang Fu · 3 shared papers, 2019–2022 · strength 0.28
  15. Li-Peng Hu · 3 shared papers, 2019–2021 · strength 0.26
  16. Shu‐Heng Jiang · 3 shared papers, 2019–2021 · strength 0.26
  17. Baiyong Shen · 2 shared papers, 2019–2023 · strength 0.22
  18. Rong Hua · 3 shared papers, 2019–2020 · strength 0.22
  19. Ping Lu · 2 shared papers, 2020–2022 · strength 0.20
  20. Ningning Niu · 2 shared papers, 2020–2022 · strength 0.20
  21. Dejun Liu · 2 shared papers, 2020–2022 · strength 0.20
  22. Jing Xue · 2 shared papers, 2020–2022 · strength 0.20
  23. Rongkun Li · 2 shared papers, 2019–2021 · strength 0.18
  24. Qin Yang · 2 shared papers, 2019–2021 · strength 0.18
  25. Jiän Zhang · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.